溶栓疗法对急性心肌梗死(AMI)的效果,部分决定于症状发生后何时给予治疗。欧洲心肌梗死计划(EMIP)组的153个试验中心旨在评价住院前溶栓疗法对疑诊AMI病人的好处和危险,并与住院病人症状发生在6小时内的溶栓疗法相比较。方法多中心双盲对照研究症状发生后6小时内的病人,心电图具有≥2个肢导联ST段括高1mm或2个心前导联ST段抬高2mm或两者,随机指定在住院前静注甲氧苯酰纤溶酶原链激酶激活剂(anistreplase,APSAC)30U,住院后给安慰剂 The effect of thrombolytic therapy on acute myocardial infarction (AMI) depends, in part, on when treatment is to be given after symptoms have occurred. The 153 trial centers in the EMIP group evaluated the benefits and risks of prethrombolytic therapy for suspected AMI patients compared with thrombolytic therapy inpatient symptoms within 6 hours. Methods A multicenter, double-blind, controlled study of patients within 6 hours of symptom onset with electrocardiographic ECG with ≥ 1 lead ST segment elevation 1 mm or 2 anterior ST segment elevation 2 mm or both randomized pre-hospital static Methyl benzoyl plasminogen streptokinase activator (anistreplase, APSAC) 30U, after admission to placebo